Mar 4, 2026 05:00PM
Feb 24, 2026 08:45AM
Jan 21, 2026 08:45AM
Jan 21, 2026 08:45AM
Jan 12, 2026 08:45AM
Jan 12, 2026 08:45AM
Jan 6, 2026 02:26PM Lucid Capital Markets Reiterates Buy Rating on Actuate Therapeutics (ACTU)
Jan 6, 2026 08:45AM
Jan 6, 2026 08:45AM
Dec 18, 2025 08:45AM
Dec 18, 2025 08:45AM
Dec 15, 2025 08:45AM
Dec 15, 2025 08:45AM
Sep 23, 2025 06:37AM H.C. Wainwright Reiterates Buy Rating on Actuate Therapeutics (ACTU)
Sep 22, 2025 08:45AM
Sep 22, 2025 08:45AM
Aug 26, 2025 01:08AM
Aug 6, 2025 08:45AM
Aug 6, 2025 08:45AM
Jul 21, 2025 06:46AM
Jul 17, 2025 08:45AM Actuate Therapeutics reports positive phase 1 results for cancer drug
Jul 17, 2025 08:45AM
Jun 24, 2025 09:15AM
Jun 20, 2025 08:45AM
Jun 20, 2025 08:45AM
Jun 16, 2025 08:30AM
Jun 2, 2025 09:00AM
May 31, 2025 04:30PM Actuate Therapeutics Presents Topline Elraglusib Phase 2 Data at ASCO 2025 Annual Meeting: Trial Meets Primary Endpoint of Median Overall Survival and Doubles 1-Year Survival in First-Line Treatment o
May 22, 2025 05:29PM
May 22, 2025 05:05PM
May 7, 2025 08:00AM
May 6, 2025 08:01AM
May 6, 2025 08:00AM
Apr 30, 2025 08:00AM
Apr 23, 2025 10:24AM Actuate to Present Elraglusib Phase 2 Topline Data at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting
Apr 17, 2025 08:00AM
Mar 27, 2025 04:01PM
Feb 25, 2025 08:04AM
Feb 25, 2025 08:00AM
Feb 6, 2025 08:00AM
Jan 7, 2025 08:03AM
Jan 7, 2025 08:00AM Actuate Therapeutics Receives EMA Orphan Medicinal Product Designation for Elraglusib for the Treatment of Pancreatic Cancer
Dec 17, 2024 08:02AM
Dec 17, 2024 08:00AM
Nov 12, 2024 08:04AM
Nov 12, 2024 08:00AM
Sep 11, 2024 08:00AM
Sep 11, 2024 08:00AM
Sep 9, 2024 08:01AM Actuate Therapeutics (ACTU) Obtains Complete Responses and Provides Update on Clinical Trial of Elraglusib for the Treatment of Relapsed/Refractory Ewing Sarcoma
Sep 9, 2024 08:00AM

312,667 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All